AU2014315026A1 - Methods of determining response to therapy - Google Patents

Methods of determining response to therapy Download PDF

Info

Publication number
AU2014315026A1
AU2014315026A1 AU2014315026A AU2014315026A AU2014315026A1 AU 2014315026 A1 AU2014315026 A1 AU 2014315026A1 AU 2014315026 A AU2014315026 A AU 2014315026A AU 2014315026 A AU2014315026 A AU 2014315026A AU 2014315026 A1 AU2014315026 A1 AU 2014315026A1
Authority
AU
Australia
Prior art keywords
metadoxine
mice
erk
subject
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014315026A
Other languages
English (en)
Inventor
Yaron DANIELY
Jonathan Rubin
Johanna SCHUMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcturus Therapeutics Ltd
Original Assignee
Alcobra Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed by Alcobra Ltd filed Critical Alcobra Ltd
Publication of AU2014315026A1 publication Critical patent/AU2014315026A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2014315026A 2013-09-09 2014-09-09 Methods of determining response to therapy Abandoned AU2014315026A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US61/875,384 2013-09-09
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US14/038,258 2013-09-26
US201461991351P 2014-05-09 2014-05-09
US61/991,351 2014-05-09
PCT/US2014/054816 WO2015035402A1 (en) 2013-09-09 2014-09-09 Methods of determining response to therapy

Publications (1)

Publication Number Publication Date
AU2014315026A1 true AU2014315026A1 (en) 2016-03-24

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014315026A Abandoned AU2014315026A1 (en) 2013-09-09 2014-09-09 Methods of determining response to therapy
AU2014316779A Abandoned AU2014316779A1 (en) 2013-09-09 2014-09-09 Methods of treating fragile X Syndrome and related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2014316779A Abandoned AU2014316779A1 (en) 2013-09-09 2014-09-09 Methods of treating fragile X Syndrome and related disorders

Country Status (12)

Country Link
EP (2) EP3044589A1 (fi)
JP (2) JP2016530291A (fi)
KR (2) KR20160086818A (fi)
CN (2) CN105917225A (fi)
AU (2) AU2014315026A1 (fi)
CA (2) CA2922901A1 (fi)
EA (2) EA201690559A1 (fi)
IL (2) IL244343A0 (fi)
MX (2) MX2016003006A (fi)
SG (2) SG11201601830PA (fi)
TW (2) TW201605443A (fi)
WO (2) WO2015033224A2 (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431442B (zh) * 2013-07-31 2018-08-07 Udc 爱尔兰有限责任公司 发光的二氮杂苯并咪唑碳烯金属配合物
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (zh) * 2017-03-24 2018-09-14 华东师范大学 一种基于数据分析技术的自闭症社交能力评估系统
EP3773538A1 (en) * 2018-04-13 2021-02-17 Healx Limited Treatment of fragile x syndrome
KR20190121569A (ko) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물
CA3102786A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigab atrin in the treatment of developmental disorders
US20230024384A1 (en) * 2020-01-08 2023-01-26 Neuroventi Composition comprising lisuride compound for treating fragile x syndrome or related developmental disorders
KR102398219B1 (ko) * 2020-02-07 2022-05-17 주식회사 뉴로벤티 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
EA023758B1 (ru) * 2009-06-25 2016-07-29 Алкобра Лтд. Применение метадоксина для лечения синдрома дефицита внимания/гиперактивности (adhd/add)

Also Published As

Publication number Publication date
CA2923421A1 (en) 2015-03-12
IL244453A0 (en) 2016-04-21
KR20160078956A (ko) 2016-07-05
JP2016530536A (ja) 2016-09-29
SG11201601830PA (en) 2016-04-28
TW201605443A (zh) 2016-02-16
CN105517546A (zh) 2016-04-20
SG11201601605YA (en) 2016-04-28
EA201690557A1 (ru) 2016-07-29
JP2016530291A (ja) 2016-09-29
MX2016003002A (es) 2016-09-08
AU2014316779A1 (en) 2016-03-17
MX2016003006A (es) 2016-06-10
CN105917225A (zh) 2016-08-31
WO2015035402A1 (en) 2015-03-12
WO2015033224A2 (en) 2015-03-12
WO2015033224A3 (en) 2015-07-02
CA2922901A1 (en) 2015-03-12
TW201606304A (zh) 2016-02-16
EP3043792A2 (en) 2016-07-20
IL244343A0 (en) 2016-04-21
EP3044589A1 (en) 2016-07-20
KR20160086818A (ko) 2016-07-20
EA201690559A1 (ru) 2016-08-31

Similar Documents

Publication Publication Date Title
AU2014315026A1 (en) Methods of determining response to therapy
Oosterhof et al. Homozygous mutations in CSF1R cause a pediatric-onset leukoencephalopathy and can result in congenital absence of microglia
Taubes et al. Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease
Stessman et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases
Bölte et al. The contribution of environmental exposure to the etiology of autism spectrum disorder
Fromer et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia
Ozkul et al. A heritable profile of six miRNAs in autistic patients and mouse models
Jang et al. Genetic correlation, pleiotropy, and causal associations between substance use and psychiatric disorder
Haberman et al. Prominent hippocampal CA3 gene expression profile in neurocognitive aging
Wells et al. The anatomical distribution of genetic associations
Dana et al. Disregulation of autophagy in the transgenerational Cc2d1a mouse model of autism
Webberley et al. The impact of probiotic supplementation on cognitive, pathological and metabolic markers in a transgenic mouse model of Alzheimer’s disease
Wang et al. Genome-wide gene by lead exposure interaction analysis identifies UNC5D as a candidate gene for neurodevelopment
US9851355B2 (en) Methods of determining response to therapy
JP2016521987A (ja) 抑うつ症状及び不安症状の少なくとも一方を有する患者における、ｃｒｈｒ１アンタゴニスト及びｖ１ｂアンタゴニストの少なくとも一方に対する治療応答を予測する方法
Ogawa et al. Expression of autophagy-related proteins in the spinal cord of Pembroke Welsh Corgi dogs with canine degenerative myelopathy
Percy et al. Is heart disease a risk factor for low dementia test battery scores in older persons with Down syndrome? Exploratory, pilot study, and commentary
Sokol et al. The genetics of autism
Zhuang et al. Mega-analysis of gene expression in mouse models of Alzheimer’s Disease
Garrett et al. Post-synaptic scaffold protein TANC2 in psychiatric and somatic disease risk
JP2023506637A (ja) 双極性障害の診断及び治療におけるＳｙｎａｐｔｏｔａｇｍｉｎ－７の使用
Kaare et al. Depression-Associated Negr1 Gene-Deficiency Induces Alterations in the Monoaminergic Neurotransmission Enhancing Time-Dependent Sensitization to Amphetamine in Male Mice
Runge et al. Disruption of the transcription factor NEUROD2 causes an autism syndrome via cell-autonomous defects in cortical projection neurons
Du et al. Developing a novel immune infiltration-associated mitophagy prediction model for amyotrophic lateral sclerosis using bioinformatics strategies
Sannah Hippocampal Differential Gene Expression Converges Across Animal Models of Mood Disorder: Results From An Interactive Meta-Analysis Pipeline Encompassing Five Animal Models

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period